FTRE vs RVTY
FTRE: Fortrea is a global contract research organization that accelerates the delivery of life-changing treatments by providing flexible, science-driven clinical development solutions to pharmaceutical and medical device partners. RVTY: Revvity is a leading health science technology company providing integrated workflows and reagents spanning drug discovery, development, and diagnostic applications across life sciences and diagnostics markets.
Side-by-side fundamentals
| Metric | FTRE | RVTY | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $18.49 | $110.54 | |
| Market cap as of 2026-07-23 | $1.7B | $12.3B | |
| P/E as of 2026-07-23 | n/a | 51.44 | |
| PEG as of 2026-07-23 | 0.50 | 5.11 | FTRE lower |
| Net margin as of 2026-07-23 | -16.5% | +8.3% | RVTY higher |
| Gross margin as of 2026-07-23 | +18.9% | +54.3% | RVTY higher |
| Operating margin as of 2026-07-23 | -13.1% | +12.4% | RVTY higher |
| ROE as of 2026-07-23 | -79.1% | +3.3% | RVTY higher |
| ROA as of 2026-07-23 | -16.3% | +2.0% | RVTY higher |
| Debt / equity as of 2026-07-23 | 2.00 | 0.45 | RVTY lower |
| Revenue growth (YoY) as of 2026-07-23 | +0.9% | +4.8% | RVTY higher |
| Revenue CAGR (3y) SEC XBRL | -1.4% | -9.3% | FTRE higher |
| Dividend yield as of 2026-07-23 | n/a | +0.3% | |
| Dividend streak (yrs) SEC XBRL | n/a | 3 | |
| Beta as of 2026-07-23 | 2.02 | 1.07 | |
| 1-year return as of 2026-07-22 close | +218.8% | +15.0% | FTRE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.